Publications scientifiques sur le VIH
Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects.
2015
Clin Pharmacokinet.
González-Sales M, Barrière O, Tremblay PO, et al.
54(3):285-294.
Subcutaneous ibalizumab in at-risk healthy subjects [abstract].
2014
Ernst J, Keefer M, Lalezari J, et al.
54th Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC); September 5-9, 2014; Washington, DC, USA.
Effect of tesamorelin on visceral fat and liver fat in HIV-infected patients with abdominal fat accumulation: a randomized clinical trial.
2014
JAMA.
Stanley TL, Feldpausch M, Oh J, et al.
312(4):380-389.
The effects of tesamorelin on phosphocreatine recovery in obese subjects with reduced GH.
2014
J Clin Endocrinol Metab.
Makimura H, Murphy CA, Feldpausch MN, Grinspoon SK.
99(1):338-343. Epub 2013 Dec 20.
Anti-CD4 monoclonal antibody ibalizumab exhibits breadth and potency against HIV-1, with natural resistance mediated by the loss of a V5 glycan in envelope.
2013
J Acquir Immune Defic Syndr.
Pace CS, Fordyce MW, Franco D, et al.
62(1):1-9.